英格兰Ⅰ期非小细胞肺癌肺叶切除与SABR治疗后的生存差异
该研究基于2015年国家肺癌审计数据库关联数据,比较ⅠA-ⅠB期、PS 0-2的NSCLC患者接受肺叶切除或SABR后的生存。共纳入2373例(SABR 476例),SABR组诊断至治疗中位间隔73天,手术组17天。早期生存相似,但1年及2年时手术组生存更优(校正OR 2.12,95%CI 1.35-2.31),SABR延迟可能贡献于较差的长期结局。
要点
- Ⅰ期NSCLC肺叶切除后1年及2年生存优于SABR,校正OR 2.12(95%CI 1.35-2.31)。
- SABR组诊断至治疗中位间隔73天,手术组17天,延迟可能影响长期结局。
- 年龄增大和PS恶化与选择SABR而非手术相关。
核心结论
- 肺叶切除患者生存优于SABR患者,但SABR治疗延迟可能贡献于较差的长期结局。
- 减少SABR治疗延迟应成为服务发展和重组的关键重点。
研究设计与样本
- 基于2015年国家肺癌审计数据库,关联住院统计和放疗数据集,识别ⅠA-ⅠB期、PS 0-2的NSCLC患者。
- 共纳入2373例患者,其中476例接受SABR。
- 评估诊断和治疗日期后90天、6个月、1年和2年的死亡可能性。
主要发现
- 手术组诊断至治疗中位间隔17天,SABR组73天。
- 年龄增大和PS恶化与接受SABR而非手术相关。
- 早期生存相似,但1年时手术组优于SABR组(校正OR 2.12,95%CI 1.35-2.31)。
- 差异在2年时持续存在,且限于年龄<80岁、PS 0-1、仅ⅠA期患者时仍存在。
关键数值与推荐
- 校正OR 2.12(95%CI 1.35-2.31)对应1年时手术 vs SABR的生存比较。
临床怎么用
- 对于适合手术的Ⅰ期NSCLC患者,肺叶切除可能提供更好的长期生存。
- 应关注并减少SABR从诊断到治疗的延迟,以改善长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 15%-20% of all non-small cell lung cancer (NSCLC) cases present with stage I disease. Surgical resection traditionally offers the best chance of a cure but some patients will not have this treatment due to older age, comorbidities or personal choice. Stereotactic ablative radiotherapy (SABR) has become an established curative intent treatment option for patients who are not selected for or do not choose surgery. The aim of this study is to compare survival at 90 days, 6 months, 1 year and 2 years for patients who received either lobectomy or SABR. METHODS: We used data from the 2015 National Lung Cancer Audit database and linked with Hospital Episode Statistics and the radiotherapy dataset to identify patients with NSCLC stage IA-IB and performance status (PS) 0-2 who underwent surgery or SABR treatment. We assessed the likelihood of death at 90 days, 6 months, 1 year and 2 year after diagnosis and procedure date to observe survival between two patient groups. RESULTS: We identified 2373 patients in our cohort, 476 of whom had SABR. The median difference between date of diagnosis and date of treatment for surgery patients was 17 days while for SABR patients it was 73 days. Increasing age and worsening PS were associated with having SABR rather than surgery. Survival between the two treatment modalities was similar early on but by 1-year people who had surgery did better than those who had SABR (adjusted ORs 2.12, 95% CI 1.35 to 2.31). This difference persisted at 2 years and when the analysis was restricted to patients aged <80 years and with PS 0 or 1 and stage IA only. CONCLUSION: Our analysis suggests that patients who have lobectomy have a better survival compared with SABR patients; however, we found considerable delays in patients receiving SABR which may contribute to poorer long-term outcomes with this treatment option. Reducing these delays should be a key focus in development and reorganisation of services.
引用
- Khakwani A, Harden S, Beckett P, et al. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England. Thorax. 2019. PMID: 31879316. doi:10.1136/thoraxjnl-2018-212493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。